Menu
Recruiting NCT07442513

Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT

Phase III Interventional Hematopoietic Stem Cell Transplantation Thrombocytopenia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: etamsylate, Placebo.
Who it may be relevant to
Registry conditions: Hematopoietic Stem Cell Transplantation, Thrombocytopenia. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Comparison of Etamsylate Versus Placebo to Prevent Bleeding in Hematopoietic Stem Cell Transplantation Recipients：a Randomized, Double-blind, Phase 3, Clinical Study

Overview

This study employs a prospective, randomized, double-blind, placebo-controlled design. It aims to compare the efficacy of etamsylate versus placebo in preventing bleeding complications in patients with thrombocytopenia following hematopoietic stem cell transplantation.

Detailed description

This study employs a prospective, randomized, double-blind, placebo-controlled design. It aims to compare the efficacy of etamsylate versus placebo in preventing bleeding complications in patients with thrombocytopenia following hematopoietic stem cell transplantation. The primary endpoint is the incidence of death or bleeding events (WHO grade ≥2) within 30 days. Secondary endpoints focus on the safety profile of etamsylate versus placebo.

Interventions

  • Drug etamsylate
    etamsylate Injection, administer by intravenous infusion, diluted with 100ml of 0.9% Sodium Chloride Injection, twice daily.
  • Drug Placebo
    0.9% Sodium Chloride Injection, 100 ml, twice daily, intravenous drip

Primary outcome measures

  • WHO grade 2 or higher bleeding events or death. [Time frame: 30 days]
Secondary outcome measures (2)
  • The number of days without WHO grade 2 or higher bleeding events [Time frame: 30 days]
  • The number of platelet transfusions [Time frame: The number of platelet transfusions within 30 days of medication administration. Etamsylate will be considered effective compared to placebo when the number of platelet transfusions in the experimental group is 2.5 fewer than in the placebo group.]

Eligibility criteria

Inclusion criteria

  • Age between 18 and 70 years (inclusive), regardless of gender;
  • Patients diagnosed with a hematological disease requiring hematopoietic stem cell transplantation;
  • Expected platelet count ≤ 10 x 10⁹/L persisting for 5 days or more;
  • Normal coagulation function;
  • Adequate organ function: Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 3 times the Upper Limit of Normal (ULN), Total Bilirubin ≤ 2 x ULN; Serum Creatinine ≤ 2 x ULN; Creatinine Clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula); Left Ventricular Ejection Fraction (LVEF) ≥ 50% as measured by Echocardiography (ECHO);
  • Voluntary provision of signed informed consent, with the ability to understand and comply with all study requirements.

Exclusion criteria

  • Diagnosis of acute promyelocytic leukemia confirmed according to WHO diagnostic criteria;
  • Pregnant or breastfeeding women, and women of childbearing potential unwilling to use effective contraception;
  • Presence of active bleeding or infection;
  • History of diagnosed primary immune thrombocytopenia or hemolytic uremic syndrome;
  • Patients with known hereditary or acquired hemorrhagic disorders;
  • Patients receiving anticoagulant or antiplatelet therapy;
  • Patients with severe cardiac insufficiency (left ventricular ejection fraction \[EF\] < 60%); or severe arrhythmias: history of clinically significant QTc prolongation (male > 450 ms; female > 470 ms), ventricular tachycardia, atrial fibrillation, second-degree heart block; myocardial infarction within 1 year prior to enrollment; or symptomatic coronary artery disease requiring medication; patients with severe liver impairment (liver function indices \[ALT, TBIL\] > 3 times the upper limit of normal \[ULN\]);
  • Patients with severe pulmonary insufficiency (obstructive and/or restrictive ventilatory defects);
  • Patients with severe renal insufficiency (renal function index \[Cr\] > 2 times ULN); or 24-hour urinary creatinine clearance rate (Ccr) < 50 ml/min;
  • Patients with mental disorders or other conditions preventing provision of informed consent and compliance with study treatment and procedural requirements;
  • Other reasons deemed by the investigator to make the patient ineligible for inclusion.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Prevention

Study locations

China · 1 center
  • The First Affiliated Hospital, College of Medicine, Zhejiang University — Hangzhou

Identifiers

NCT: NCT07442513 · ZJU-HSCT-ETA

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗